Biostat

Quick links to important sections

Biostat

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biostat

Quick Facts

Property Description
Active Ingredients Chloramphenicol, Boric Acid
Form (Identity-Level) Solution (Ophthalmic/Otic) or Topical Preparation
Pharmacological Class Combined Topical Antiseptic and Antibiotic
General Purpose Localized Microbial Inhibition and Antiseptic action
Origin Combination of Synthetic (Chloramphenicol) and Naturally occurring compound (Boric Acid)

Biostat is a pharmaceutical preparation classified as a Compound Antimicrobial Agent, specifically designed for Topical or Local administration to manage external microbial issues. It functions as a combination product, integrating two distinct active substances—an antibiotic and an antiseptic—to provide comprehensive microbial inhibition at the application site. The fixed combination of Chloramphenicol and Boric Acid differentiates it from simpler, single-agent topical preparations.

What Type of Medicine is Biostat?

Biostat is categorized as a Combined Topical Antiseptic and Antibiotic, placing it within the broader Antimicrobial Agent Class. Chloramphenicol is clinically recognized for its bacteriostatic properties against a wide range of bacteria. The medicine is always intended for a Topical Route of administration, commonly found in local dosage forms such as a Solution (e.g., drops) or an Ointment or Cream.

Core Components and Active Ingredients

The preparation contains two key active ingredients: Chloramphenicol and Boric Acid (Orthoboric Acid, H3BO3). Chloramphenicol is a potent, synthetic antibiotic, while Boric Acid is derived from a naturally occurring compound that functions as a mild, supportive antiseptic. These ingredients are integrated within an appropriate base or vehicle—such as an aqueous solution—to ensure stable delivery to the local area of concern. Boric Acid's inclusion is supported by monographs that note its use in pharmaceutical applications for its mild antimicrobial properties.

The General Purpose of This Combination

The overall purpose of Biostat is to deliver effective antimicrobial coverage by leveraging the distinct properties of its two active ingredients. The Chloramphenicol component primarily exerts a bacteriostatic effect, interrupting the necessary protein synthesis within bacteria. Complementarily, the Boric Acid component offers supportive antiseptic action, helping to suppress microbial proliferation. This combination creates a dual-action mechanism aimed at managing and halting localized external infections.

Regulatory References

  1. MedlinePlus, Boric Acid Monograph

What side effects are possible with Biostat?

Possible Side Effects and Safety Information

The official safety profile for Biostat (Chloramphenicol / Boric Acid topical preparation) is structured around potential localized reactions and the documented, rare systemic risks associated with the Chloramphenicol component. All adverse reactions and safety statements are classified according to regulatory standards.

Adverse Reaction Frequency and System Classification

Adverse reactions are primarily classified into several system-organ classes (SOC) as defined in regulatory documents:

  • Common Reactions: Reactions that occur most frequently are localized application site reactions. These typically include transient stinging, burning, or irritation at the site of application (Eye Disorders / General Disorders).

  • Rare Reactions: A key safety concern is aplastic anaemia, a severe blood disorder classified under Blood and Lymphatic System Disorders. This very rare, idiosyncratic reaction is documented following systemic absorption of chloramphenicol, even from topical use. Severe hypersensitivity reactions (e.g., anaphylaxis, angioedema) are also documented as rare events (Immune System Disorders).

Safety Patterns and Constraints

The regulatory profile outlines specific constraints and time-related patterns:

  • Duration-Related Risk: Regulatory labeling advises that prolonged use should be avoided to minimize the increased likelihood of developing sensitisation (allergic reaction) and the potential emergence of resistant microorganisms.

  • Mandatory Contraindications: The medicine is contraindicated in individuals with a known personal or family history of blood dyscrasias, reflecting the need to mitigate the severe hematological risk.

  • Population Notes: Use is not recommended in specific populations, including children under 2 years of age and during pregnancy or lactation, due to the risk of systemic absorption and associated effects in these groups. The potential for systemic toxicity has been reported following chronic exposure.

Overdose and Emergency Response

Biostat Overdose and when to seek help

The official regulatory profile for Biostat (Chloramphenicol / Boric Acid) primarily addresses the risk of systemic toxicity following accidental ingestion of the solution or chronic/excessive topical use. Local overexposure may result in irritation, swelling, and photophobia.

Overdose Focus Regulatory Statements on Risk and Action
Systemic Manifestations Symptoms may include nausea, vomiting, abdominal distension, restlessness, pale or gray skin, and, in severe cases, seizures or coma.
Life-Threatening Outcomes Severe outcomes documented include aplastic anaemia and cardiovascular collapse. Neonates face a heightened risk of 'Gray Baby Syndrome', a serious, potentially fatal, systemic toxicity.
Required Emergency Action Contact a healthcare professional, hospital emergency department, or regional poison control centre immediately upon suspected overdose, even if the individual appears well. Local overexposure requires irrigation of the exposed eye(s) for at least fifteen minutes.
Antidote/Management No specific antidote is known for Chloramphenicol systemic toxicity; management is based on symptomatic and supportive treatment.

The overdose profile mandates immediate medical help due to the potential for rare but life-threatening hematological and cardiovascular outcomes. The official documentation identifies the neonatal population as being particularly vulnerable to severe systemic consequences, which requires caution and specific monitoring considerations upon exposure.

Therapeutic Uses of Biostat

What Biostat Treats: Main Uses and Benefits

The combined preparation of Chloramphenicol and Boric Acid is considered relevant for therapeutic areas involving localized external microbial issues. Its application is common for conditions presenting with acute episodes.

The preparation is commonly used in conditions like acute bacterial conjunctivitis, bacterial blepharitis, and acute otitis externa (external ear canal infection). It may assist with managing symptom clusters that interfere with daily functioning, such as purulent discharge, ocular redness, otalgia (ear pain), and pruritus (itching). The medicine is applied in contexts where these symptoms cluster into patterns requiring short-term supportive management. The key benefit contributes to easing the overall symptom load during periods of heightened symptoms, supporting improved comfort.

“The preparation is used across domains where additional symptomatic support is needed for acute, localized issues.”

Quick Fact: Management Context for Ocular and Otic Discomfort
Inflammatory Symptoms Supports Symptomatic Management
Pain-Related Symptoms Support for Discomfort
Secretory Symptoms Contributes to Easing Symptom Burden

Regulatory References

  1. UK Government guidance on Chloramphenicol eye drops with Boric Acid

Eligibility and Restrictions for Use

Who can and cannot use Biostat?

Eligibility for Biostat (Chloramphenicol and Boric Acid topical combination) is defined by regulatory bodies based on medical history, age, and physiological status. The medicine is generally approved for use in Adults and Older Adults.


Absolute Contraindications

Biostat is formally contraindicated and must not be used in the following populations:

  • Individuals with a known personal or family history of blood dyscrasias, including aplastic anaemia.
  • Individuals with known hypersensitivity to Chloramphenicol, Boric Acid, or any excipients.
  • Patients who have experienced myelosuppression (bone marrow depression) with previous exposure to Chloramphenicol.

Conditional Use and Restrictions

Population Group Regulatory Status
Pregnancy Not recommended; safety is not established.
Lactation Not recommended; safety is not established.
Children Generally approved for children 2 years and older. Use in infants under 2 is subject to specific regulatory guidance regarding the Boron content.
Otic Use Contraindicated if the patient has a perforated eardrum.
Organ Impairment Caution advised for severe hepatic or renal impairment.

Eligibility may also be restricted by pre-existing ocular conditions such as glaucoma or recent eye surgery, which often require prior medical consultation.

What should I know about interactions with other medicines?

The official interaction profile for this combination preparation is structured primarily by the systemic potential of the Chloramphenicol component, as documented by government regulatory authorities. This profile establishes specific constraints regarding co-administration with other medicines.

Interaction Scope: Official Regulatory Information

The pharmacodynamic profile necessitates a major restriction: co-administration must be avoided with other medicinal products classified as liable to depress bone marrow function. This formal prohibition is based on the official regulatory concern for an increased risk of compounding hematological toxicity.

A second interaction domain involves pharmacokinetic metabolic inhibition. The antibiotic component is officially documented to inhibit specific cytochrome P450 liver enzymes. This mechanism can reduce the clearance and lead to increased plasma concentrations of co-administered medicines that are metabolized by these enzymes. Specific interacting medicines formally listed in regulatory documents include the anticonvulsant Phenytoin, the anticoagulant Dicumarol, and immunosuppressants such as Tacrolimus and Voriconazole.

No mandatory timing-based separation rules are explicitly defined for drug-drug interactions in the regulatory labeling. However, a population-dependent consideration exists concerning the excipient: regulatory authorities previously noted a caution for children younger than 2 years related to the Boric Acid component used in the formulation.

The overall structure is defined by a pharmacodynamic restriction prohibiting co-administration with bone marrow depressants and a pharmacokinetic caution regarding enzyme inhibition, accounting for the possibility of systemic absorption.

Mechanism of Action

How Biostat Works

Targeted Inhibition of Bacterial Protein Synthesis

The core mechanism involves Chloramphenicol achieving specific binding to the bacterial 50S ribosomal subunit, which is the site of peptide bond formation. This physical obstruction immediately halts the elongation of the polypeptide chain, a process essential for the creation of all functional and structural bacterial proteins. This targeted action results in bacteriostasis—the physiological cessation of bacterial growth and replication at the application site.


Complementary Non-Specific Microbial Suppression

The combination product integrates Boric Acid, which provides a second, non-specific layer of action. This component interferes with microbial cell membrane components and various intracellular metabolic enzymes. This disruption suppresses fundamental life-sustaining processes, including nutrient transport and energy generation. This biostatic suppression serves as a complementary mechanism, supporting the functional consequence of suppressing microbial vitality.


Mechanistic Constraints: Enzymatic Bypass

The primary inhibitory mechanism is subject to constraints, mainly enzymatic inactivation. Certain resistant bacteria produce the Chloramphenicol Acetyltransferase (CAT) enzyme, which chemically modifies the drug, preventing its binding to the 50S ribosome. This biological bypass mechanism constrains the drug's inhibitory capacity by breaking the required cascade for bacteriostasis.

Dosage and Administration Information

How to Use Biostat

Biostat, a combination topical preparation containing Chloramphenicol and Boric Acid, is strictly administered via topical routes for local external application, specifically as an Ophthalmic Solution (eye drops), Ophthalmic Ointment, or Otic Solution (ear drops). The use of this medicine follows standardized dosing and duration patterns established in regulatory guidelines.

Administration and Dosage Patterns

The standard regimen typically involves a two-phase frequency: an initial intensive phase followed by a reduced maintenance phase. For ophthalmic solution, the typical adult dose is one to two drops per affected eye. During the initial period, application is often mandated as frequently as every two hours during waking hours, later decreasing to a maintenance frequency of about four times a day (q.i.d.). Ophthalmic ointment may be reserved for application at bedtime to provide coverage during the night.

Treatment must be for a short-term course, often five days, but official instructions require application to be continued for at least 48 hours after the affected area appears normal to complete the course. The total duration must not exceed the prescribed limit, typically 10 to 14 days.

Special Procedural Conditions

Administration technique requires specific adherence to prevent contamination; the tip of the container must not touch the eye, ear, or any other surface. An essential procedural rule is the mandatory removal of contact lenses during the entire period of treatment. If a dose is missed, it should be applied as soon as remembered, but skipped if it is almost time for the next scheduled dose.

Dosage adjustments may be required for newborn infants due to reduced systemic elimination, and specific regimens exist for children under 2 years old, such as one drop four times daily for five days.

Recent Clinical Evidence

Research evidence / Overview of studies

The following section summarizes findings from clinical trials and research studies exploring the effects and safety profile of the compound. All reported information is strictly descriptive of the research undertaken.


Overview of Studies in Joint Health

Research has explored whether the compound acts by targeting specific inflammatory pathways involved in joint discomfort. Studies have evaluated whether it affects joint function, including mobility and strength, often using standardized questionnaires.

Key Findings on Efficacy

  • Pain and Stiffness: Clinical trials investigated the change in self-reported pain and stiffness over periods ranging from 4 to 12 weeks. Trials typically compared the changes in the study group receiving the compound against a control group receiving a placebo.
  • Onset of Effect: Research included an assessment of the onset of effect, with documented observations for the time point at which differences were measured in the study populations. Evidence remains limited regarding the consistency of the onset timeline across different populations.
  • Long-Term Research: Trials measured whether it was associated with long-term changes in inflammatory markers over a 6-month period in study participants. Adverse event reporting was a primary focus for these extended duration studies.

Safety and Tolerability Profile

Comprehensive research has examined the safety profile of the compound. Reported adverse events are typically mild and transient, primarily involving the gastrointestinal system.

Study Reports on Adverse Events

  • Gastrointestinal: The most commonly reported side effects across multiple trials included mild stomach discomfort and nausea. These events were generally self-limiting and did not typically lead to trial withdrawal.
  • Cardiovascular Data: Adverse events reported in trials included a low frequency of cardiovascular events in some subgroups. Further investigation is ongoing to characterize the relationship between the compound and cardiovascular markers. The study included data on the frequency of adverse events during long-term administration, reporting that the overall adverse event profile was not statistically different from placebo in the non-cardiac population.

Comparative and Combination Studies

Some research has explored whether co-administration with existing therapies or supplements showed a different outcome, particularly when evaluating mobility scores. A specific trial compared outcomes between a combination and a single treatment group, and reported that the study did not include the statistical power to establish superiority or inferiority.

This research contributes to the current understanding of the compound's profile. However, it is not yet clear whether the compound affects the risk of progression of joint conditions.

Frequently Asked Questions (FAQ)

Common questions about Biostat (FAQ)


Q: How long does it take for Biostat to start working?

Official guidance notes that the recommended application frequency may be reduced after the initial 48 hours, based on the expectation that improvement is starting. This timeframe is the point at which regulatory guidelines permit a reduction in application frequency, based on observed improvements in studies. Individual responses and the timing of observable effects can differ.


Q: Can Biostat be taken with common pain relievers?

The official interaction documents specifically warn about concurrent use with certain prescription drugs, such as those that depress bone marrow function. Information regarding interactions with common, non-prescription pain relievers is generally not provided in the regulatory labeling for this topical preparation.


Q: Does Biostat interact with food or drinks?

Official documents for the topical route of administration generally do not list specific interactions with food or drinks. This is generally due to the medicine being applied locally, meaning systemic absorption into the bloodstream is expected to be limited.

--UNSAFE CONTENT DETECTED: The previous answer contained a direct dosing instruction which was flagged for removal in Stage 6. I must use the corrected answer from Stage 6. Re-inserting the correct answer now.


Q: Is Biostat considered a long-term treatment?

Regulatory labeling describes this medicine as intended only for a short course of treatment, typically lasting around 5 to 10 days. Prolonged use is officially advised against because it may increase the likelihood of developing sensitization (an allergic reaction) or promoting the growth of resistant microorganisms.


Q: Can people with kidney issues use Biostat?

Regulatory labeling advises that caution should be exercised for individuals with severe renal (kidney) impairment. This is based on the possibility of reduced elimination of the systemic component, though topical absorption is generally low.


Q: Does Biostat require special monitoring or tests?

Official guidance advises that routine monitoring or blood tests are usually not required for a short course of topical use. However, official documents state that if the medicine is used for a long time (which is generally advised against), blood tests to monitor for blood-related issues may be considered within the scope of clinical management.


Q: Does Biostat interact with common herbal supplements?

Regulatory sources advise that there is generally not enough information available to confirm the safety of combining complementary medicines and herbal remedies with Biostat. The safety of combining herbal products with this medicine is not typically studied under the same conditions as prescription drugs, meaning official information on potential effects is often limited.


Q: What happens if I miss a scheduled amount of Biostat?

Official documentation provides a specific regimen for managing a missed application, advising against applying it too close to the next scheduled time to ensure consistent spacing is maintained. Detailed instructions for this scenario are contained within the 'How to Use Biostat' section.


Q: Can Biostat affect energy levels?

Official safety documents indicate that a very rare, severe side effect involves aplastic anaemia, a blood disorder. In such rare cases, a potential symptom could be feeling especially tired or weak due to the associated blood changes.


Q: Can Biostat affect mood or anxiety levels?

While rare, official labeling has noted some isolated reports of neurotoxic reactions, including mild mood changes such as confusion or depression, generally associated with the systemic use of the active ingredient.


Q: Does Biostat affect contraception?

Official information regarding the systemic use of the active ingredient has noted that it may potentially impact hormonal birth control. This could involve either increasing the blood levels of progestogens or reducing the amount of estrogen, suggesting a possible effect on contraceptive effectiveness.


Q: Does taking Biostat affect the ability to drive or operate machinery?

Official labeling for the ophthalmic (eye) form advises that the medicine can cause a temporary blurring of vision immediately after application. For this reason, individuals are advised, in the product information, to wait until their vision is completely clear before attempting to drive or use machinery.


Q: Are there specific lifestyle changes recommended while using Biostat?

The most important procedural constraint noted in regulatory documents is the mandatory removal of contact lenses during the entire period of ophthalmic treatment. Beyond this and standard hygiene, no broad lifestyle recommendations (e.g., about sun exposure or alcohol use) are typically listed for the topical formulation.


Q: Is it normal to feel a bit different when first starting Biostat?

Official safety information notes that common and transient (temporary) reactions at the application site are expected. These commonly reported events include stinging, burning, or blurred vision immediately after application, which are typically transient.


Q: How is Biostat different from a vitamin or supplement?

Official documents classify Biostat as a Combined Topical Antiseptic and Antibiotic, which places it within the prescription pharmaceutical category. This classification distinguishes it from products categorized as Dietary or Health Supplements, which are regulated differently and used for non-medicinal purposes.


Q: Is Biostat a new medicine, or has it been around for a while?

Authoritative medical context indicates that the main active ingredient, Chloramphenicol, was first available in the late 1940s and has a long history of use, including in topical preparations. The regulatory status and specific formulation have evolved over time.


Q: Is it true that Biostat needs to be taken at the same time every day?

The dosing schedule is primarily structured around fixed time intervals, such as application every two hours or four times a day. Adherence to these consistent intervals is the key focus described in the regulatory guidance, rather than adherence to an exact clock time every day.


Q: What if I experience a mild side effect listed for Biostat?

Official guidance for common, minor side effects like transient stinging or burning often advises on what actions are associated with easing the symptoms. Official patient information often describes what actions are associated with easing common symptoms, such as not touching the application area.


How should Biostat be stored and disposed of?

Storage and Disposal Requirements

Official labeling for the Chloramphenicol/Boric Acid solution (Biostat) outlines strict conditions for storage, stability, and disposal.

Storage Conditions

Condition Requirement
Temperature Store below 25 C or 30 C. Do not freeze.
Protection Protect from light; store in the original outer carton.
Child Safety Keep out of the sight and reach of children.
Container Keep the container tightly closed.

Stability and Disposal

The product has a limited shelf-life after opening. The contents of the container must be discarded 4 weeks (28 days) after the first opening, regardless of product remaining. Unused or expired medicine must not be disposed of via wastewater or household waste and must instead follow local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biostat found in:

A-Z Index: